Want to see BRNS full AI Analyst Report?
Top Page
Barinthus Biotherapeutics
(NASDAQ:BRNS)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.64
▼(-3.03% Downside)
Action:Reiterated
Date:08/06/26
The score is primarily held down by weak financial performance (zero TTM revenue, large ongoing losses, and sustained cash burn) and bearish technicals (price below key moving averages with negative MACD). Corporate events are mixed—transaction progress is constructive, but Nasdaq compliance/listing pressure is a meaningful risk—while valuation is constrained by negative earnings and no dividend support.
Positive Factors
Low financial leverage
Low debt relative to equity limits interest and refinancing pressure, giving Barinthus more flexibility to fund clinical programs and pursue strategic options while operating as a development-stage biotechnology company.
Negative Factors
No current commercial revenue
The absence of recurring product revenue leaves the company dependent on clinical execution, partnerships, and external financing, making earnings visibility weak until a candidate is successfully commercialized.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Low debt relative to equity limits interest and refinancing pressure, giving Barinthus more flexibility to fund clinical programs and pursue strategic options while operating as a development-stage biotechnology company.
Read all positive factors
Barinthus Biotherapeutics (BRNS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$26.96M
Dividend YieldN/A
Average Volume (3M)124.73K
Price to Earnings (P/E)―
Beta (1Y)1.98
Revenue Growth-100.00%
EPS Growth41.21%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.03
Shares Outstanding40,848,892
10 Day Avg. Volume97,530
30 Day Avg. Volume124,726
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.38
Price to Sales (P/S)0.00
P/FCF Ratio-0.59
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$6.00Price Target Upside809.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.14
Revenue Forecast (FY)N/A
Barinthus Biotherapeutics Business Overview & Revenue Model
Company Description
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprie...
How the Company Makes Money
Barinthus Biotherapeutics primarily makes money through a combination of: (1) collaboration, licensing, and partnership-related revenue (such as upfront payments, research funding, and potential development/regulatory/sales milestone payments), wh...
Barinthus Biotherapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 14.97M | 802.00K | 44.70M | 268.00K |
| Gross Profit | -1.76M | -5.86M | 14.97M | 802.00K | 44.70M | 268.00K |
| EBITDA | -37.52M | -62.90M | -55.37M | -71.06M | 5.19M | -47.87M |
| Net Income | -41.74M | -66.58M | -61.07M | -73.35M | 5.34M | -50.87M |
Balance Sheet | ||||||
| Total Assets | 81.89M | 98.17M | 160.33M | 214.51M | 270.20M | 280.71M |
| Cash, Cash Equivalents and Short-Term Investments | 59.30M | 70.46M | 110.66M | 142.09M | 194.38M | 214.05M |
| Total Debt | 10.29M | 11.28M | 12.01M | 12.98M | 8.77M | 7.22M |
| Total Liabilities | 24.76M | 23.88M | 30.19M | 27.51M | 27.00M | 28.15M |
| Stockholders Equity | 57.07M | 74.21M | 130.03M | 186.78M | 242.90M | 252.13M |
Cash Flow | ||||||
| Free Cash Flow | -26.43M | -48.02M | -29.83M | -56.34M | -20.57M | -33.73M |
| Operating Cash Flow | -26.43M | -47.98M | -28.94M | -50.92M | -14.43M | -32.58M |
| Investing Cash Flow | 569.00K | 416.00K | -892.00K | -5.41M | -5.75M | -12.91M |
| Financing Cash Flow | 0.00 | 2.00K | 2.16M | 1.87M | 325.00K | 222.74M |
Barinthus Biotherapeutics Risk Analysis
Barinthus Biotherapeutics disclosed 108 risk factors in its most recent earnings report. Barinthus Biotherapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Barinthus Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $46.65M | -1.03 | -160.72% | ― | 893.01% | 41.74% | |
49 Neutral | $276.55M | -1.75 | -90.30% | ― | ― | 48.20% | |
48 Neutral | $66.88M | -1.02 | -70.89% | ― | ― | 1.11% | |
44 Neutral | $26.96M | -0.69 | -63.87% | ― | -100.00% | 41.21% | |
44 Neutral | $11.06M | -3.13 | -70.74% | ― | 373.88% | -59.79% | |
40 Underperform | $5.48M | -0.30 | -160.28% | ― | -84.26% | 14.73% |
* Healthcare Sector Average
BRNS
Barinthus Biotherapeutics
0.71
-0.47
-40.12%
CLGN
Collplant Holdings
0.31
-2.46
-88.92%
ALXO
ALX Oncology Holdings
1.98
0.84
73.68%
ALGS
Aligos Therapeutics
7.51
-3.55
-32.10%
GDTC
CytoMed Therapeutics Limited
1.00
-1.00
-50.20%
BOLD
Boundless Bio Inc.
2.92
1.78
155.70%
Barinthus Biotherapeutics Corporate Events
Business Operations and StrategyDelistings and Listing ChangesM&A Transactions
Barinthus Advances Clywedog Merger and Nasdaq Relisting Plans
Neutral
Aug 25, 2026
On August 24, 2026, Barinthus Biotherapeutics announced progress on its all-stock combination with Clywedog Therapeutics, including plans to delist its American Depositary Shares from Nasdaq and transfer the listing to a new parent company, Beacon...
Executive/Board ChangesDelistings and Listing ChangesDividendsRegulatory Filings and ComplianceShareholder Meetings
Barinthus Biotherapeutics Holds 2026 Annual General Meeting
Negative
Jul 2, 2026
Barinthus Biotherapeutics held its 2026 Annual General Meeting on July 2, 2026, where shareholders approved all resolutions, including the re-election of directors Karen T. Dawes and Anne M. Phillips and the reappointment and remuneration authoriz...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.